Skip to main content

Advertisement

Table 2 Physicochemical properties of synthesized compounds

From: Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study

Compound Chemical structure Mol. wt Mol. formula Rf valuea (%) Yielda M.Pt (°C)
5a 385.44 C19H19N3O4S 0.67 75.4 234–235
5b 417.44 C19H19N3O6S 0.65 73.8 255–256
7 395.47 C21H21N3O3S 0.62 76.4 210–211
9a 356.37 C19H20N2O5 0.59 73.5 230–231
9b 372.44 C19H20N2O4S 0.74 72.8 210–211
11 341.36 C18H19N3O4 0.69 74.1 204–205
13a 314.33 C18H18O5 0.70 73.8 199–200
13b 284.31 C17H16O4 0.75 69.3 178–179
13c 284.31 C17H16O4 0.83 73.7 157–159
13d 300.37 C17H16O3S 0.84 75.9 182–184
16 340.37 C20H20O5 0.67 69.9 120–122
17 294.34 C19H18O3 0.79 72.4 178–179
  1. aMobile phase—5a11-methanol-ethyl acetate–benzene (30:30:40 v/v/v), 13a17-acetone–toluene (30:70, v/v)